Menu
Search
|

Menu

Close
X

AC Immune SA ACIU.OQ (NASDAQ Stock Exchange Global Market)

11.79 USD
+0.07 (+0.60%)
As of 8:59 PM GMT
chart
Previous Close 11.72
Open 11.60
Volume 83,348
3m Avg Volume 26,103
Today’s High 12.12
Today’s Low 11.58
52 Week High 13.91
52 Week Low 6.24
Shares Outstanding (mil) 56.77
Market Capitalization (mil) 639.40
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.33 Mean rating from 3 analysts

KEY STATS

Revenue (mm, CHF)
FY17
4
FY16
23
FY15
39
EPS (CHF)
FY17
-0.536
FY16
-0.167
FY15
0.392
*Note: Units in Millions of Swiss Francs
**Note: Units in Swiss Francs

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
113.23
5.77
Price to Book (MRQ)
vs sector
5.17
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.32
16.52
LT Debt to Equity (MRQ)
vs sector
0.32
12.22
Return on Investment (TTM)
vs sector
-32.55
14.43
Return on Equity (TTM)
vs sector
-33.72
16.13

EXECUTIVE LEADERSHIP

Martin Velasco
Chairman of the Board of Directors, Since
Salary: --
Bonus: --
Andrea Pfeifer
Chief Executive Officer, Since 2003
Salary: --
Bonus: --
Joerg Hornstein
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Andreas Muhs
Chief Scientific Officer, Since 2005
Salary: --
Bonus: --
Friedrich von Bohlen und Halbach
Member of Board of Director, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

EPFL Innovation Park, Building B
LAUSANNE     1015

Phone: +4121.3459121
Site:

AC Immune SA is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson's, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology platforms. The Company's pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn, among others.

SPONSORED STORIES